Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Neoplasms 5Solid Tumors 4Primary Myelofibrosis 4Leukemia, Myeloid, Acute 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Solid Tumor 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoid Malignancy 1Leukemia, Myelomonocytic, Chronic 1Leukemia, B-Cell 1Leukemia 1Hepatitis C 1Hepatitis B 1Hematologic Neoplasms 1Fibrosis 1Carcinoma, Hepatocellular 1Advanced Lung Non-Squamous Non-Small Cell Carcinoma 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × navitoclax × Clear all
NCT00878449 2018-06-06

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

AbbVie

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumors

NCT00887757 2017-11-21

Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
46 enrolled
Other solid neoplasm

Solid Tumors

NCT00891605 2017-11-21

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
19 enrolled
Other solid neoplasm

Solid Tumors

NCT01009073 2017-11-20

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

AbbVie

Phase 1 Completed
51 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡